Aptevo Therapeutics Inc. (NasdaqCM: APVO)
Health Care · Biotechnology · US
$2.41
-10.07% today · -92.2% 1Y
Aptevo Therapeutics Inc. (NasdaqCM: APVO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $4.83M and employs 33 people.
Over the last twelve months the share price has lost 92.2%, trading between 2.58 and 48.78.
Tweenvest scores Aptevo Therapeutics Inc. across four factors: quality 27/100. Its strongest factor is quality.
APVO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $4.83M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -29.72
- Dividend yield
- —
- Beta (5Y)
- 1.65
- 52-week high
- $48.78
- 52-week low
- $2.58
- Avg volume (3M)
- —
- Shares outstanding
- 1.80M
- Employees
- 33
- Next earnings
- —
About Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset, Aptevo's research pipeline encompasses several preclinical compounds. These include ALG.APV-527, an experimental bispecific ADAPTIR molecule designed to target both 4-1BB (CD137) and 5T4, a tumor-specific antigen prevalent in numerous cancer types. Another promising candidate is APVO603, a dual agonist bispecific antibody that targets both 4-1BB and OX40. The company is also advancing APVO442, a bispecific agent leveraging its ADAPTIR-FLEX platform technology to improve the precise delivery of drugs to prostate-specific membrane antigen (PSMA)-positive tumors for the treatment of prostate cancer. To further its development efforts for ALG.APV-527, Aptevo maintains a collaborative partnership and option agreement with Alligator Bioscience AB. Founded in 2016, Aptevo Therapeutics Inc. operates from its headquarters located in Seattle, Washington.
- ISIN
- US03835L7029
- Founded
- 2016
- Listed since
- Jul 20, 2016
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.